NCT06669078View on ClinicalTrials.gov

NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

October 15, 2027

Study Completion Date

October 15, 2027

Conditions

Locally Advanced Pancreatic Cancer

Interventions

DRUG

Nal-lRl+Oxaliplain+5- FU +PD 1

Nal-lRl+Oxaliplatin+5- FU +PD-1, these drugs are given on d1, d15, 28 days as one cycle, SBRT is performed during the third and fourth cycle.

DRUG

Nal-lRl+Oxaliplain+5- FU

Nal-lRl+Oxaliplatin+5- FU, these drugs are given on d1, d15, 28 days as one cycle.

All Listed Sponsors

lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

NCT06669078 - NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter